DBV Technologies to Attend Upcoming Investor Conferences
(Thomson Reuters ONE) -
Press Release
Montrouge, France, May 2, 2017
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced that members of its management team will present and host
investor meetings at the following upcoming investor conferences:
Susanna Mesa, Senior Vice President, Strategy, will present at the Bank of
America Merrill Lynch 2017 Health Care Conference in Las Vegas, NV, on
Wednesday, May 17, 2017, at 9:20 am PT.
Pierre-Henri Benhamou, Chairman & Chief Executive Officer, David Schilansky,
Chief Operating Officer & Deputy Chief Executive Officer, and Sébastien
Robitaille, Deputy Chief Financial Officer, will host investor meetings at the
Gilbert Dupont 15(th) Annual Healthcare Conference on Tuesday, May 30, 2017, in
Paris, France.
Susanna Mesa, Senior Vice President, Strategy, will present at the Barclays West
Coast Biopharma Conference in Calistoga, CA, on Thursday, June 1, 2017, at
10:30 am PT.
Pierre-Henri Benhamou, Chairman & Chief Executive Officer, and David Schilansky,
Chief Operating Officer & Deputy Chief Executive Officer, will host investor
meetings at the Société Générale 12(th) Edition of the Nice Conference on
Friday, June 2, 2017, in Nice, France.
A live webcast of the Bank of America Merrill Lynch 2017 Health Care Conference
will be available on the Investor Relations section of the Company's website:
http://www.dbv-technologies.com/en/investor-relations. A replay of the
presentation will also be available on DBV's website within three hours after
the event.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2100702/796354.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.05.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 539498
Anzahl Zeichen: 4268
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies to Attend Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
